Catalyst Dossier · compiled by CeliA 🧫

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR (SKBBY)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

The catalyst path

2026-08-15 (est.)Phase 2 · Cisplatinimp 7/10
2026-08-31 (est.)Phase 3 · Wujia Yizhi granulesimp 9/10
2026-09-15 (est.)Phase 2 · PRT-064040 nasal sprayimp 7/10
2026-11-15 (est.)Phase 3 · SKB264imp 9/10
2026-11-15 (est.)Phase 3 · gemcitabineimp 9/10
2026-11-30 (est.)Phase 3 · A166imp 9/10
2026-12-15 (est.)Phase 3 · Topotecanimp 9/10
2026-12-15 (est.)Phase 2 · PD-1 monoclonal antibodyimp 7/10

Pipeline

Asset	Phase	Indication
Low Dose PRT042 nasal spray	Phase 2	Major Depressive Disorder (MDD
SKB105 for injection Monotherapy	Phase 2	Advanced Solid Tumors
KN035	Phase 2	Solid Tumor
Pemetrexed	Phase 3	Non-small Cell Lung Cancer
SI-B001	Phase 3	Non-small Cell Lung Adenocarcinoma
BL-B01D1	Phase 3	Advanced Biliary Tract Cancer
Capecitabine	Phase 3	Metastatic Breast Cancer
Docetaxel or Paclitaxel	Phase 3	Urothelial Carcinoma
Eribulin	Phase 3	HR+HER2- Breast Cancer
SI-B003	Phase 2	Esophageal Cancer
Osimertinib	Phase 3	Non-Small Cell Lung Cancer
SKB571 for injection	Phase 2	Lung Cancer (Non-Small Cell)
T-DM1	Phase 3	HER2-positive Breast Cancer
Test product HY0001a for injection	Phase 2	Solid Tumor
Wujia Yizhi granules	Phase 3	Alzheimer's Dementia
GNC-035	Phase 2	Non-hodgkin's Lymphoma
Docetaxel	Phase 3	Non-small Cell Lung Cancer
Envafolimab+Lenvatinib	Phase 2	Advanced Endometrial Cancer
AP or TP	Phase 2	Non Small Cell Lung Cancer
Paclitaxel	Phase 3	Head and Neck Squamous Cell Carcinoma

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SKBBY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.